Categories: News

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T.

To join the call:

  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Please visit this link for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on August 5, 2021 at 12 p.m. ET.

About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
ian.karp@intelliatx.com

Lina Li
Director, Investor Relations
+1-857-706-1612
lina.li@intelliatx.com

Media:
Matt Crenson
Ten Bridge Communications
+1-917-640-7930
media@intelliatx.com
mcrenson@tenbridgecommunications.com

Staff

Recent Posts

OrthoMinds, LLC Provides Notice of a Data Security Event

ALPHARETTA, Ga., March 20, 2025 /PRNewswire/ -- OrthoMinds, LLC ("OrthoMinds") is providing notice of a…

16 minutes ago

HealthMark Named a Top Workplace in 2025 by USA Today

HealthMark Group celebrates another year as a USA Today Top Workplace honoree, which recognizes companies…

16 minutes ago

Danaher Schedules First Quarter 2025 Earnings Conference Call

WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its…

6 hours ago

Angelalign Technology Achieves Steady Growth in 2024, Driven by Global Expansion and Digital Innovation

SAN CLEMENTE, Calif., March 20, 2025 /PRNewswire/ -- Angelalign Technology Inc. ("Angelalign Technology" or the "Company")…

6 hours ago

Steer Health Launches SteerConnect: The First AI-Powered Digital Gateway to Streamline Patient Care Access

Innovative platform eliminates endless scrolling and care dead-ends with smart triage, personalized care matching, and…

6 hours ago

Sciton Inc. Recognized as a 2025 Top Workplace USA for the Fourth Consecutive Year

PALO ALTO, Calif., March 20, 2025 /PRNewswire/ -- Sciton Inc., a global leader in laser…

6 hours ago